Compare Crispr Therapeutics AG (CRSP) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Microchip Technology Inc. — how do they compare? Crispr Therapeutics AG trades at $50.36 (market cap $4.97B), while Microchip Technology Inc. trades at $85.15 (market cap $47.30B). The key difference: Microchip Technology Inc. is far larger — about 9.5× Crispr Therapeutics AG's market cap, and Microchip Technology Inc. pays a 2.09% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MCHP | |
|---|---|---|
Market Cap | $4.97B | $47.30B |
Sector | Health | Technology |
52-Week High | $76.78 | $102.97 |
52-Week Low | $44.34 | $49.02 |
Enterprise Value | $3.32B | $52.60B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Microchip Technology (MCHP) trades at $84.23, down 4.92% in the last session, with a bearish technical signal and support near $81. The company reported a net loss of -$500K in 2025 despite beating EPS estimates in recent quarters, while revenue declined to $4.40B. Analyst consensus remains strongly bullish with a $113.33 price target, supported by positive news on AI and aerospace demand.
MCHP faces near-term pressure from weak profitability and high debt, but long-term growth is supported by AI, data center, and aerospace exposure. Risks include cyclical semiconductor demand and execution challenges, yet institutional sentiment and recent product launches suggest potential recovery if earnings improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
